Life Sciences Greenhouse of Central Pennsylvania

A Venture Capital Investment Company for Life Sciences Enterprises in Central Pennsylvania

  • About Us
    • About LSGPA
    • Our Team
    • Board of Directors
  • The Funding Process
  • Resources
    • The Ecosystem
    • Applicant Support
    • Why Central PA?
  • Portfolio Companies
    • Portfolio Overview
    • Devices and Diagnostics
    • Drug Discovery
    • Other
  • News and Events
    • Press Releasees
    • Video Gallery
  • Apply Now
  • Contact Us

Archives for January 2020

MacuLogix Introduces the AdaptDx Pro Guided by Theia

January 17, 2020 By Admin

The next generation of dark adaptation testing features a wearable headset and an artificial intelligence-driven onboard technician.

HARRISBURG, PENNSYLVANIA, JANUARY 14, 2020–MacuLogix®, Inc., the only company to equip eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with age-related macular degeneration (AMD), announces the next generation of dark adaptation functional testing with the introduction of the AdaptDx Pro™ guided by Theia.™

The company’s original AdaptDx® automated dark adaptometer was introduced in 2014 and has since been used by more than 1,000 eye care professionals to identify and monitor AMD. The new AdaptDx Pro headset was custom-designed and tested for patient comfort and includes all the functionality and accuracy of the company’s table-top dark adaptometer. As a self-contained wearable headset, the AdaptDx Pro requires no darkroom or external computer and features an artificial intelligence-driven onboard technician named Theia.™  After the in-office technician selects the testing protocol and places the device on the patient’s head, Theia takes over to facilitate a reliable, consistent testing experience by using automated instructions and adaptive feedback spoken directly to the patient.

 “What makes the AdaptDx Pro so special is that it combines high-tech innovation and high-touch patient care without sacrificing functionality or results,” says William McPhee, President and CEO at MacuLogix. “AdaptDx Pro makes it simple to fit dark adaptation testing into any practice workflow and Theia frees up the technician to focus on other valuable tasks.”

Impaired dark adaptation is the earliest biomarker of AMD. Often manifested as night vision problems, this functional impairment becomes apparent years before drusen are visible. Therefore, assessing how well patients’ eyes can adapt from bright light to darkness makes it possible to detect AMD at a subclinical stage. AdaptDx Pro guided by Theia is a revolutionary new way to measure dark adaptation in a clinical setting quickly and effectively, using an objective, functional measurement called the Rod Intercept™ (RI™). Importantly, impaired dark adaptation as measured by the AdaptDx Pro is 90% specific and sensitive to AMD.

“Patients and staff love Theia. Her gentle coaching, combined with the well-designed, comfortable headset puts patients at ease and frees up technicians while testing takes place,” says MacuLogix’s clinical advisor Jeffry Gerson, OD, FAAO. “Ultimately, the AdaptDx Pro enables us to test more patients to find disease that we may have otherwise missed and start those patients on a treatment plan to slow disease progression.”

Years of development went into creating this one-of-a-kind medical device to improve the testing experience and make modern AMD management practical in almost any optometry or ophthalmology office.

“After spending more than two years developing this technology, I firmly believe the AdaptDx Pro and Theia are going to change the future of AMD by eliminating virtually every barrier to in-office diagnosis and management of age-related macular degeneration,” says MacuLogix Co-founder and Chief Technology Officer Gregory Jackson, PhD. “Not only is the entire experience improved for everyone involved, but the addition of Theia’s artificial intelligence helps ensure consistent, reliable testing results.”

The AdaptDx Pro launches today and the company has committed to providing current AdaptDx table-top device owners with the first opportunity to upgrade to the AdaptDx Pro. Eye care professionals can experience the AdaptDx Pro guided by Theia in person and learn about purchase and subscription pricing options at variety of local and national events, including SECO (Booth 838) and Vision Expo East (Booth MS4733) or online at www.maculogix.com.

About MacuLogix®

MacuLogix, Inc. equips eye care professionals with the instrument, tools and education needed to effectively diagnose, manage and treat patients with age-related macular degeneration (AMD). By leveraging the science of dark adaptation through its AdaptDx® and AdaptDx Pro™ guided by Theia™, MacuLogix is working to eliminate preventable blindness caused by AMD—a chronic, progressive disease that impacts over 170 million people worldwide and goes undiagnosed in 25 percent of patients. Dark adaptation functional testing technology from MacuLogix enables eye care professionals to detect, monitor and treat AMD three years before it can be seen clinically. MacuLogix also provides each customer with in-practice training and treatment best practices to support the implementation and optimization of dark adaptation testing. Visit www.maculogix.com for additional information.

Filed Under: News and Events

Latest News

Saladax Biomedical Expanding Access to Antipsychotic Drug Testing With Beckman Coulter Partnership

Apr 11, 2022 | Kelsy Ketchum NEW YORK – Measuring the presence of antipsychotic drugs in a patient's system is currently a time-consuming and … Read More...

THE LIFE SCIENCES GREENHOUSE OF CENTRAL PA ANNOUNCES CHANGE IN LEADERSHIP

President and CEO Mel Billingsley, PhD, Retiring after 20 Years at Helm Harrisburg, PA  ̶  March 24, 2022.  The Life Sciences … Read More...

Saladax Biomedical and HLS Therapeutics Strengthen Partnership With an Exclusive Distribution Agreement for Canada

BETHLEHEM, Pa.--(BUSINESS WIRE)--Saladax Biomedical, Inc (Saladax) is pleased to announce an exclusive distribution agreement with HLS Therapeutics … Read More...

Immunomic Therapeutics Announces Collaboration With iOncologi

ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc., (“ITI”) a privately held clinical-stage biotechnology company focused on advancing its … Read More...

Immunomic Therapeutics Expands Board of Directors with Appointments of Two New Members

ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical stage biotechnology company pioneering the study of … Read More...

Archives

  • April 2022
  • December 2021
  • August 2021
  • July 2021
  • April 2021
  • March 2021
  • January 2021
  • November 2020
  • July 2020
  • April 2020
  • January 2020
  • September 2019
  • August 2019
  • May 2019
  • March 2019
  • February 2019
  • January 2019
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • June 2017
  • March 2017
  • January 2017
  • October 2016
  • September 2016
  • August 2016
  • June 2016
  • May 2016
  • January 2016

LSGPA
Life Sciences Greenhouse of Central Pennsylvania
225 Market Street
Suite 500
Harrisburg, PA  17101
1-717-635-2100

Strawberries
LSGPA Copyright © 2018

Copyright © 2022 · WordPress · Log in